Tofersen: The first therapy to target a genetic factor in ALS
ADC评论
July 29, 2022
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALSCAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE)
